<div class="table-wrap table anchored whole_rhythm" id="t4-copd-13-1229">
<h3>Table 4</h3>
<!--caption a7--><div class="caption"><p id="__p50">Effect of IND/GLY on individual outcome measures compared with LABA + ICS</p></div>
<div data-largeobj="" data-largeobj-link-rid="largeobj_idm139931944302672" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table">
<thead><tr>
<th rowspan="1" colspan="1" valign="top" align="left">Outcome measures</th>
<th rowspan="1" colspan="1" valign="top" align="left">IND/GLY (n=811)</th>
<th rowspan="1" colspan="1" valign="top" align="left">LABA + ICS (n=269)</th>
<th rowspan="1" colspan="1" valign="top" align="left">IND/GLY versus LABA + ICS odds ratio (95% CI)</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Decrease in trough FEV<sub>1</sub> of ≥100 mL</td>
<td rowspan="1" colspan="1" valign="top" align="left">126 (15.5)</td>
<td rowspan="1" colspan="1" valign="top" align="left">61 (22.7)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.66 (0.47–0.93)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Decrease in TDI of ≥1 point</td>
<td rowspan="1" colspan="1" valign="top" align="left">91 (11.2)</td>
<td rowspan="1" colspan="1" valign="top" align="left">39 (14.5)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.81 (0.54–1.21)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Increase in CCQ of ≥0.4 point</td>
<td rowspan="1" colspan="1" valign="top" align="left">113 (13.9)</td>
<td rowspan="1" colspan="1" valign="top" align="left">48 (17.8)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.79 (0.54–1.15)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Incidence of AECOPD<sup>a</sup>
</td>
<td rowspan="1" colspan="1" valign="top" align="left">63 (7.8)</td>
<td rowspan="1" colspan="1" valign="top" align="left">16 (5.9)</td>
<td rowspan="1" colspan="1" valign="top" align="left">1.33 (0.76–2.35)</td>
</tr>
</tbody>
</table></div>
<div id="largeobj_idm139931944302672" class="largeobj-link align_right" style="display: none"><a target="object" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909796/table/t4-copd-13-1229/?report=objectonly">Open in a separate window</a></div>
<div class="tblwrap-foot">
<div id="idm139931938044432"><p id="__p51" class="p p-first-last"><strong>Notes:</strong></p></div>
<div id="tfn8-copd-13-1229">
<sup>a</sup>As
 adverse event reporting. Data presented as number and percentage of 
patients with clinically important deterioration, unless otherwise 
specified.</div>
<div id="tfn9-copd-13-1229"><p id="__p53" class="p p-first-last"><strong>Abbreviations:</strong> AECOPD, acute exacerbation of moderate/severe COPD; CCQ, clinical COPD questionnaire; FEV<sub>1</sub>, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; IND/GLY, indacaterol/glycopyrronium; LABA, long-acting β<sub>2</sub>-agonist; TDI, transition dyspnea index.</p></div>
</div>
</div>